United States
Print page content Print
Increase text size Decrease text size
Text Size

Glossary of oncology terms and definitions

Mechanism of Action


Angiogenesis: Physiological process involving growth of new blood vessels from preexisting vessels

Antiangiogenic: substance that inhibits angiogenesis

RTK: receptor tyrosine kinase


Other


MCT: Mast Cell Tumor

HRQL: Health-Related Quality of Life

C-ACTC: Canine-Adapted Common Toxicity Criteria (an adaptation for canines of the National Cancer Institute's Common Toxicity Criteria version 2.0). National Cancer Institute, outlined in the Cancer Therapy Evaluation Program’s Common Toxicity Manual, Version 2.0 (June 1999) adapted for dogs.


Receptors


VEGF: vascular endothelial growth factor

PDGF: platelet-derived growth factor

VEGFR: vascular endothelial growth factor receptor

PDGFR: platelet-derived growth factor receptor

SCF: stem cell factor

c-kit: is a Proto-oncogene. c-kit is the receptor for stem cell factor (SCF)

Growth factor: substances capable of stimulating cellular growth, proliferation and differentiation by binding to specific receptors on the surface of target cells.

Growth factor receptor: cell surface receptor that growth factors bind to


Responses


RECIST: Response Evaluation Criteria in Solid Tumors. A set of published guidelines for defining tumor response

Target lesions: Measurable lesions up to a maximum of three lesions; at least one target lesion had to measure ≥ 20 mm at baseline; a lymph node could qualify as a target lesion. (Zoetisdata on file, study 1963C-60-04-688)

Non-target lesions: All lesions other than the target lesions were identified as non-target lesions and their existence recorded at baseline; measurements were of non-target lesions were not required; a lymph node could qualify as a non-target lesion. (Zoetisdata on file, study 1963C-60-04-688)

Complete Response (CR): disappearance of all target and non-target lesions and the appearance of no new lesions

Objective Response Rate (ORR): defined as complete or partial response

Progressive Disease (PD): at least a 20% increase in the sum of the longest diameter of target lesions using the smallest sum of the longest diameter recorded since treatment initiated as the reference, progression of nontarget lesions, or appearance of a new lesion(s).

Partial Response (PR): at least a 30% decrease in the sum of the longest diameter of target lesions, nonprogression of nontarget lesions, and no new lesion(s).

Stable Disease (SD): non-Partial Response / non-Progressive Disease

Biological Response: Responses defined by stable disease ≥10 weeks, complete response or partial response

IMPORTANT SAFETY INFORMATION: During clinical studies, the most common adverse events associated with PALLADIA included: diarrhea, anorexia (including decreased appetite), lethargy, neutropenia, emesis, lameness, weight loss, musculoskeletal disorder, and blood in stool/GI bleed/hemorrhagic diarrhea. PALLADIA may cause vascular dysfunction, which can lead to edema and thromboembolism, including pulmonary thromboembolism. Serious and sometime fatal GI complications, including GI perforation, have occurred rarely in dogs treated with PALLADIA. If GI ulceration is suspected stop drug administration and treat appropriately. Children should not come in contact with PALLADIA. In addition, all individuals, including children and pregnant women, should avoid direct contact with broken or partially dissolved PALLADIA tablets or biological waste from dogs treated with PALLADIA. To report a suspected adverse reaction call Zoetis at 1-888-963-8471. See full Prescribing Information

All trademarks are the property of Zoetis Inc., its affiliates and/or its licensors. Zoetis Inc. All rights reserved. August 2015. PAL-00040